GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (SHSE:688505) » Definitions » Earnings Yield (Joel Greenblatt) %

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (SHSE:688505) Earnings Yield (Joel Greenblatt) % : 26.67% (As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Earnings Yield (Joel Greenblatt) %?

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Enterprise Value for the quarter that ended in Jun. 2024 was ¥5,465.8 Mil. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was ¥132.7 Mil. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2024 was 26.67%.

The historical rank and industry rank for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

SHSE:688505' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: 1.17   Med: 3.19   Max: 31.35
Current: 2.3

During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co was 31.35%. The lowest was 1.17%. And the median was 3.19%.

SHSE:688505's Earnings Yield (Joel Greenblatt) % is ranked worse than
50.76% of 1048 companies
in the Drug Manufacturers industry
Industry Median: 2.375 vs SHSE:688505: 2.30

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2024 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Earnings Yield (Joel Greenblatt) % Chart

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings Yield (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.70 9.08 10.34 6.71 8.02

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Quarterly Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Earnings Yield (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.10 8.02 11.79 26.67 -

Competitive Comparison of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Earnings Yield (Joel Greenblatt) %

For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % falls into.



Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Cos Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2023 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=100.594/8449.286
=1.19 %

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥132.7 Mil.



Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co  (SHSE:688505) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Business Description

Traded in Other Exchanges
Address
308 Cailun Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai, CHN, 201210
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is engaged in the research, development, manufacturing, and sale of biopharmaceutical products. Its product portfolio includes ALA (Aminolevulinic acid Hydrochloride); FuMeiDa and Libord. Geographically, it derives revenue from Mainland China.
Executives
Zhang Wen Bo Core technical personnel
Jiang Jian Ping Core technical personnel
Tao Ji Ning Core technical personnel
Shen Yi Jun Core technical personnel
Li Jun senior management
Xue Yan senior management
Wang Luo Chun Supervisors, core technical personnel
Su Yong Directors, senior managers
Zhao Da Jun Directors, senior managers
Yang Xiao Lin senior management
Gan Yi Min Senior management, core technical personnel
Yu Dai Qing Supervisors

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Headlines

No Headlines